Episode Details

## Chapters 0:00 The Sarepta Therapeutics Story 3:54 Earnings Overview Sarepta Therapeutics just reported Q1 2026 earnings — eps beats by 190%. Here's what the double beat means for SRPT and whether the bull case is playing out. 🔔 Subscribe for weekly deep dives on every Russell 1000 earnings report: https://www.youtube.com/@ChargedAlpha?sub_confirmation=1 📊 Key Financial Highlights: • Revenue: $731M vs $476M expected (+53.5% beat) • EPS: $3.16 vs $1.09 expected (+189.9% beat) 📈 Free stock screening tools — no signup, no paywall: https://chargedalpha.com 🎧 Also available as a podcast: https://chargedalpha.podbean.com #stocks #SRPT #earnings #stocks #investing #stockmarket #earningsseason #wallstreet #SareptaTherapeutics --- Financial data and charts: Financial Modeling Prep (https://financialmodelingprep.com) ⚖️ Disclaimer: This video is for informational and educational purposes only. Nothing discussed constitutes a buy, sell, or hold recommendation. All investments carry risk. Past performance does not guarantee future results. Always do your own research and consult a qualified financial advisor. Hosts may hold positions in securities discussed. This episode was researched, written, and produced using AI-assisted tools. Data sourced from public filings and may contain inaccuracies. Watch on YouTube: https://www.youtube.com/watch?v=YKDsVAZnKwQ